SECA and Bioiberica Farma encourage innovation in osteoarthritis management
10 Mar 2014
Healthcare
- The SECA and Bioiberica Farma will again award the Innova prizes to recognize the work of innovative projects contributing to improvements in osteoarthritis management and patient care.
- Deadline for candidature submissions is July 31st 2014. The two prizes, each worth 10,000€, will be awarded on October 16th, during the SECA annual congress.
Barcelona, March 3, 2014. The Spanish Society for Quality Care (SECA) and Bioiberica Farma have announced the second edition of the Innoba Awards in OA management and care quality. The aim of these awards is to recognize projects contributing to the improvement of the management of OA and OA patient care.
The prize is open to all individuals or entities, public or private, having their legal residence in Spain, and currently working on innovative projects in OA. The jury will evaluate the social impact, innovation, future reach, results achieved so far, and general consistency of their project.
“The favorable reception of the 1st edition, where professionals fully aware of the need for advances in OA patients' care presented pioneering initiatives, proved to us that today's healthcare structures are different, and that the current scientific and technological advances allow us to take more effective approaches in treating OA. Let us not forget that OA represent 30% of all work-related disabilities and 35% of all primary care consultations, mostly due to pain endured by the patients. “This second edition of the Innoba awards is an excellent opportunity to report on pioneering medical experiences in current day OA patient care,” said Dr. ManelSantiñá, general secretary of the SECA.
TheInnova awards consist of two separate prizes, each one worth €10,000. Papers can be submitted for review through the www.premiosinnoba.com website before July 31st, 2014. Submission rules can be consulted there as well. The winners will be announced around October 1st, and the awards ceremony will take place in Madrid on 16th October 2014, during the 23rd Annual congress of the Spanish Society of Quality in Healthcare (SECA).
According to Bioiberica’s CEO, Dr. José Escaich, “The diversity of specialist participating in the first edition confirmed the high social and economic impact of osteoarthritis. This is why we would like to hear from all the outstanding professionals presenting new tools that can lead to achange in OA management techniques, thus improving the quality of life for OA patients”.
About SECA
The Spanish Society for Quality in Healthcare (SECA) is a scientific, multidisciplinary society whose aims are to encourage and promote permanent quality improvements in sanitary healthcare.
The primary aim of SECA is the dissemination of the culture of quality. Their efforts are directed at convincing and engaging professionals inall specialties, scientific societies, medical colleges and all types of professional bodies, so that these professionals may incorporate the latest knowledge in quality improvement into their everyday medical practice. Another of their key objectives is to work together with political and management leaders-without their commitment, it could not be possible to implement long-term quality programs in the healthcare centers.
About Bioiberica
Prevention, diagnosis, prognosis and treatment of osteoarthritis. These are the main objectives of Bioiberica Farma, a Spanish chemical-pharmaceutical company founded in 1975 that currently is one of the leading companiesworldwide in the field of osteoarthritis care. Its main activities focus on the research and development of drugs that can efficiently treat the disease, although during the last years it has been strongly committed with personalized medicine research, that is, in the development of products that use genetic and /or environmental data in the prevention, diagnostic, prognostic or treatment of thisdisease. At the social level, the aim of Bioiberica Farma is to improve the life quality of OA patients, and to reduce the general burden of that disease.
